01 10Somatuline
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,386
2019 Revenue in Millions : 1,248
Growth (%) : 11
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,324
2020 Revenue in Millions : 1,385
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,307
2021 Revenue in Millions : 1,324
Growth (%) : -1
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,150
2022 Revenue in Millions : 1,307
Growth (%) : -13
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2015 Revenue in Millions : 317
2014 Revenue in Millions : 442
Growth (%) : 39%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 570
2015 Revenue in Millions : 426
Growth (%) : 34
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 871
2016 Revenue in Millions : 667
Growth (%) : 31
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 957
2017 Revenue in Millions : 794
Growth (%) : 21%
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2014 Revenue in Millions : 17%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,124
2018 Revenue in Millions : 923
Growth (%) : 22
LOOKING FOR A SUPPLIER?
